Loading organizations...
Cresilon: Medical device company developing and manufacturing plant-based hemostatic gels to stop bleeding for veterinary and human wound care.
Cresilon is a Brooklyn, New York-based medical device company that develops and manufactures proprietary plant-based hemostatic gels designed to rapidly stop bleeding in surgical and trauma settings. The organization produces advanced wound care technologies, including Vetigel for veterinary clinics and Traumagel for human medical applications, which serve as direct alternatives to traditional gauze. Operating as a nine-figure business, the company manufactures its products at a dedicated GMP-certified facility and has reportedly utilized its gel to save over 50,000 pets' lives across various clinical environments. While initially focused exclusively on the veterinary market, the firm is actively expanding its commercialization efforts into human trauma care to support both routine medical treatments and complex surgical operations. Originally established under the corporate name Suneris, the company was founded in 2010 by Joe Landolina and Isaac Miller.
Cresilon has raised $25.0M across 1 funding round.
Cresilon has raised $25.0M in total across 1 funding round.
Cresilon has raised $25.0M in total across 1 funding round.
Cresilon's investors include Paulson Investment Company.
Cresilon has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series A in October 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 31, 2022 | $25.0M Series A | Paulson Investment Company |